ENGN Stock Forecast & Price Target

enGene Therapeutics is facing challenges in the clinical development of detalimogene due to a decline in efficacy compared to previous interim analyses, potentially impacting its potential in the Non-Muscle Invasive Bladder Cancer market. However, the management continues to focus on improving the protocol and has reported highly favorable safety data. As a result, the market share and Probability of Success of detalimogene have been lowered, leading to a downgrade in ENGN's outlook to NEUTRAL. Further, the current 12-month CR rate estimate of 24.5% seems unlikely given the current results and may raise questions about the drug's potential approval. Additionally, our DCF analysis values ENGN at NEUTRAL using a 12% WACC, in line with other clinical-stage biotech companies.

enGene Therapeutics is facing a challenging outlook as the recent update for its lead product, detalimogene, demonstrated a weaker durability profile and raised questions about its mechanism of action. The company is still working on confirming the final analysis with the FDA and has announced a new cohort in its ongoing clinical trials, but these developments may not be enough to address concerns about regulatory approval and market potential. This, combined with increased uncertainty in its financial and commercial outlook, has led to a lowered PT and a more conservative outlook on the stock.